These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21429609)

  • 1. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial.
    Lassen P; Eriksen JG; Krogdahl A; Therkildsen MH; Ulhøi BP; Overgaard M; Specht L; Andersen E; Johansen J; Andersen LJ; Grau C; Overgaard J;
    Radiother Oncol; 2011 Jul; 100(1):49-55. PubMed ID: 21429609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer.
    Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J;
    Radiother Oncol; 2010 Jan; 94(1):30-5. PubMed ID: 19910068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.
    Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J
    J Clin Oncol; 2009 Apr; 27(12):1992-8. PubMed ID: 19289615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mature results from a Swedish comparison study of conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - The ARTSCAN trial.
    Zackrisson B; Kjellén E; Söderström K; Brun E; Nyman J; Friesland S; Reizenstein J; Sjödin H; Ekberg L; Lödén B; Franzén L; Ask A; Wickart-Johansson G; Lewin F; Björk-Eriksson T; Lundin E; Dalianis T; Wennerberg J; Johansson KA; Nilsson P
    Radiother Oncol; 2015 Oct; 117(1):99-105. PubMed ID: 26427805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer.
    Lassen P; Primdahl H; Johansen J; Kristensen CA; Andersen E; Andersen LJ; Evensen JF; Eriksen JG; Overgaard J;
    Radiother Oncol; 2014 Dec; 113(3):310-6. PubMed ID: 25544647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project.
    Lassen P; Lacas B; Pignon JP; Trotti A; Zackrisson B; Zhang Q; Overgaard J; Blanchard P;
    Radiother Oncol; 2018 Jan; 126(1):107-115. PubMed ID: 29100700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity.
    Rieckmann T; Tribius S; Grob TJ; Meyer F; Busch CJ; Petersen C; Dikomey E; Kriegs M
    Radiother Oncol; 2013 May; 107(2):242-6. PubMed ID: 23602369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma.
    Lyhne NM; Primdahl H; Kristensen CA; Andersen E; Johansen J; Andersen LJ; Evensen J; Mortensen HR; Overgaard J
    Radiother Oncol; 2015 Oct; 117(1):91-8. PubMed ID: 26255764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPV DNA in saliva from patients with SCC of the head and neck is specific for p16-positive oropharyngeal tumours.
    Wasserman JK; Rourke R; Purgina B; Caulley L; Dimitroulakos J; Corsten M; Johnson-Obaseki S
    J Otolaryngol Head Neck Surg; 2017 Jan; 46(1):3. PubMed ID: 28061890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
    Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
    J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells.
    Sørensen BS; Busk M; Olthof N; Speel EJ; Horsman MR; Alsner J; Overgaard J
    Radiother Oncol; 2013 Sep; 108(3):500-5. PubMed ID: 23953409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double positivity for HPV DNA/p16 in tonsillar and base of tongue cancer improves prognostication: Insights from a large population-based study.
    Garnaes E; Frederiksen K; Kiss K; Andersen L; Therkildsen MH; Franzmann MB; Specht L; Andersen E; Norrild B; Kjaer SK; von Buchwald C
    Int J Cancer; 2016 Dec; 139(11):2598-605. PubMed ID: 27537425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials.
    Lassen P; Overgaard J; Eriksen JG
    Radiother Oncol; 2013 Sep; 108(3):489-94. PubMed ID: 24060179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hybrid Capture 2 human papillomavirus testing of fine needle aspiration cytology of head and neck squamous cell carcinomas.
    Hakima L; Adler E; Prystowsky M; Schiff B; Schlecht N; Fox A; Suhrland M; Khader SN
    Diagn Cytopathol; 2015 Sep; 43(9):683-7. PubMed ID: 25964135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC.
    Linge A; Schötz U; Löck S; Lohaus F; von Neubeck C; Gudziol V; Nowak A; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Bunea H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Lauber K; Pigorsch S; Combs SE; Mönnich D; Zips D; Baretton GB; Buchholz F; Krause M; Belka C; Baumann M;
    Radiother Oncol; 2018 Apr; 127(1):27-35. PubMed ID: 29295747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer.
    Mortensen HR; Overgaard J; Specht L; Overgaard M; Johansen J; Evensen JF; Andersen LJ; Andersen E; Grau C
    Radiother Oncol; 2012 Apr; 103(1):69-75. PubMed ID: 22398313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
    Linge A; Lohaus F; Löck S; Nowak A; Gudziol V; Valentini C; von Neubeck C; Jütz M; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Krause M; Baumann M;
    Radiother Oncol; 2016 Dec; 121(3):364-373. PubMed ID: 27913065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
    Overgaard J; Hoff CM; Hansen HS; Specht L; Overgaard M; Lassen P; Andersen E; Johansen J; Andersen LJ; Evensen JF; Alsner J; Grau C
    Radiother Oncol; 2018 Apr; 127(1):12-19. PubMed ID: 29523409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.